Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 13 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 10 11 12 13 presentations: 1 to 25 of 301
Introduction
Lisa A Newman
Weill Cornell Medicine, New York, NY, United States
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
Colorectal cancer in Nigeria: High tech and low-tech approaches to improving patient outcomes
Olusegun I Alatise
Obafemi Awolowo Univ., Ile-Ife, Osun, Nigeria
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
Spliceomics: Alternative RNA splicing as a source of ancestry-related molecular targets in precision oncology and cancer disparities
Steven R Patierno
Duke Cancer Institute, Durham, NC, United States
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
The DARC side of breast cancer disparities: Links to African ancestry and immunologic tumor responses
Melissa B Davis
Weill Cornell Medicine, New York, NY, United States
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
Genomic and epigenomic studies of cholangiocarcinoma in diverse populations
Bin Tean Teh
National Cancer Centre Singapore, Singapore, Singapore
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
Wrap-up and opportunities for the future
Lisa A Newman
Weill Cornell Medicine, New York, NY, United States
from AACR Annual Meeting 2019 on April 1, 2019 8:15 AM-10:15 AM
Introduction
Nilofer S Azad
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Ryan J. Sullivan
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Stephen B Baylin
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy
Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
David R Gandara
UC Davis Comprehensive Cancer Ctr., Sacramento, CA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies
Julius Strauss
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Maura L Gillison
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Discussant
Taofeek Kunle Owonikoko
Emory University, Atlanta, GA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Panel Discussion
Richard Pazdur
U.S. Food and Drug Administration, Silver Spring, MD, United States
Marc Theoret
U.S. Food and Drug Administration, Silver Spring, MD, United States
Israel Lowy
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
Alan B. Sandler
Genentech, South San Francisco, CA, United States
Hesham A. Abdullah
AstraZeneca Pharmaceuticals LP, Rockville, MD, United States
Scot W. Ebbinghaus
Merck Research Laboratories - Rahway, North Wales, PA, United States
Kevin Chin
EMD Serono, Billerica, MA, United States
Fouad Namouni
Bristol-Myers Squibb Co., Lawrenceville, NJ, United States
from AACR Annual Meeting 2019 on April 1, 2019 3:00 PM-4:45 PM
Approaches to combination therapy
Peter K Sorger
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Inflammation and inflammatory mediators as potential targets for cancer prevention or interception
Raymond N DuBois
Medical Univ. of South Carolina, Charleston, SC, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Training sensei
Daniel D Von Hoff
TGen (The Translational Genomics Research Institute), Phoenix, AZ, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Drugging the undruggable: The Myc oncogene as a case study
Louis Chesler
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
High mobility group A1 (HMGA1) chromatin regulators: Revving up inflammation and developmental networks to drive tumor progression
Linda M S Resar
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Immunotherapy in AL Amyloidosis
Suzanne Lentzsch
Columbia University, New York, NY, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Impacting cancer research and patient care through circulating biomarkers
Johann S De Bono
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
In vivo systems biology approaches in cancer biology and therapeutics
Douglas A Lauffenburger
MIT, Cambridge, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
Integrating genomics into precision cancer medicine
Elaine R Mardis
Nationwide Children's Hospital, Columbus, OH, United States
from AACR Annual Meeting 2019 on April 1, 2019 7:00 AM-8:00 AM
<< first | < prev page: of 13 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 10 11 12 13 presentations: 1 to 25 of 301